Rivaroxaban‐calibrated chromogenic anti‐Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation-Reference-Cited by-同舟云学术

Rivaroxaban‐calibrated chromogenic anti‐Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation

Published:2021-10 Issue:7 Volume:5 Page:
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Lucas Fabienne¹^ORCID,Stecker Michael S.²,Pozdnyakova Olga¹,Connors Jean M.³^ORCID,Battinelli Elisabeth M.³

Affiliation:

1. Department of Pathology Brigham and Women’s Hospital Harvard Medical School Boston Massachusetts USA

2. Division of Angiography and Interventional Radiology Department of Radiology Brigham and Women’s Hospital Harvard Medical School Boston Massachusetts USA

3. Division of Hematology Department of Medicine Brigham and Women’s Hospital Harvard Medical School Boston Massachusetts USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12594

Reference15 articles.

1. Peritoneovenous shunts palliate malignant ascites

2. Ascites: Its correction by peritoneovenous shunting

3. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study

4. Rivaroxaban

5. The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One-year retrospective analysis of anti-FXa apixaban and rivaroxaban levels demonstrates utility for management decisions in various urgent and nonurgent clinical situations;American Journal of Clinical Pathology;2023-08-07